MTOR and neoplasm: This may lead to the loss function of PTEN gene, resulting in abnormal activation of the PI3K/AKT/mTOR pathway and suggesting that mTOR may be one of the effective therapeutic targets for this tumor.[36] Based on these results and clinical practice guidelines, the patient was treated with lipo‐doxorubicin, everolimus, and bevacizumab.